|
|
Vol. 11.20 – 26 May, 2022
|
|
|
|
|
|
|
|
Scientists uncovered a critical role of glycogen synthase kinase 3 (GSK3) in regulating the expression of serine/one-carbon metabolic enzymes. [Science Advances]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Researchers investigated the antagonist effects of the conserved coronavirus endoribonuclease, in combination with NS4a or NS4b.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
The authors underscored the essential role played by fibroblast growth factor receptor 2b (Fgfr2b) signaling in the maintenance of the alveolar epithelial type 2 cells (AT2s) lineage in the adult lung during homeostasis and suggested that the IAAPs could represent a new population of AT2 progenitors.
[Cellular and Molecular Life Sciences]
|
|
|
|
|
|
Hybrid nanoformulation showed no cytotoxic effects on a widely employed model of alveolar epithelial cells for a variety of concentrations and exposure times.
[Biomaterials Science]
|
|
|
|
|
|
Researchers exposed the human bronchial epithelial cell line, 16HBE, to copper and assessed the functional role of a circRNA, circ_0008882, by RNA overexpression.
[Chemosphere]
|
|
|
|
|
|
Investigators explored the cytocompatibility of Pluronics F-127.The cells were exposed to varying concentrations of Pluronics F-127 in A549 cells for 24 hours. [Environmental Science and Pollution Research]
|
|
|
|
|
|
|
|
The authors fouond that disintegrin-metalloproteinase 15 (ADAM15) regulated the epidermal growth factor receptor/focal adhesion kinase (EGFR/FAK) signaling pathway by interactions with integrins.
[Cell Death & Disease]
|
|
|
|
|
|
EGFR signaling-mediated glucose-6-phosphate dehydrogenase (G6PD) expression plays a pivotal role in paclitaxel resistance, highlighting the potential of targeting EGFR to overcome paclitaxel resistance in triple-negative breast cancer and NSCLC cells overexpressing G6PD.
[British Journal of Cancer]
|
|
|
|
|
|
Researchers established that iloprost required Frizzled9 in vivo for lung cancer chemoprevention.
[iScience]
|
|
|
|
|
|
Immunoglobulin-like domain-containing receptor 1 (ILDR1) was highly expressed in the lungs, and its expression level was increased after virus infection.
[Scientific Reports]
|
|
|
|
|
|
The authors indicated that the ADH1C/methionine adenosyltransferase axis possibly increased cisplatin resistance in lung adenocarcinoma cells.
[DNA and Cell Biology]
|
|
|
|
|
|
CRNDE knockdown inhibited the viability, migration and invasion of NSCLC cells or epidermal growth factor receptor gene-mutant NSCLC cells. [Kaohsiung Journal of Medical Sciences]
|
|
|
|
|
|
|
|
The authors summarize the evolution of mutation-based molecular subtyping of SCLC, as well as the trends in molecular targeting and immunotherapeutic for SCLC.
[Seminars in Cancer Biology]
|
|
|
|
|
|
Scientists summarize the tumor-promoting role and molecular mechanisms of cancer-associated fibroblasts in NSCLC, including their origin, phenotypic changes and heterogeneity, and their functional roles in carcinogenesis.
[International Journal of Cancer]
|
|
|
|
|
|
Myosteatosis might serve as an independent indicator of unfavorable survival outcomes for overall survival and progression-free survival in lung cancer patients. [International Journal of Clinical Oncology]
|
|
|
|
|
|
|
|
Avalo Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase II PEAK trial evaluating AVTX-002 for the treatment of NEA.
[Avalo Therapeutics, Inc.]
|
|
|
|
|
|
EpiEndo Pharmaceuticals, the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human study with EP395 in healthy subjects.
[EpiEndo Pharmaceuticals (B3CNewswire, Inc.)]
|
|
|
|
|
|
Therapeutic Solutions International announced today receiving Investigational New Drug application number #28508 from the FDA for its proposed clinical trial evaluating the JadiCellâ„¢ in treatment of COPD. [Therapeutic Solutions International (BusinessWire, Inc.)]
|
|
|
|
|
|
|
|
November 7 – 8, 2022 London, England, United Kingdom
|
|
|
|
|
|
|
|
|
|
|
Memorial Sloan Kettering Cancer Center – New York, New York, United States
|
|
|
|
|
|
|
Columbia University – New York, New York, United States
|
|
|
|
|
|
|
Francis Crick Institute – London, United Kingdom
|
|
|
|
|
|
|
Flanders Institute for Biotechnology – Brussels, Belgium
|
|
|
|
|
|
|
Mayo Clinic – Scottsdale, Arizona, United States
|
|
|
|
|
|